Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

  • STATUS
    Recruiting
  • End date
    Jun 20, 2024
  • participants needed
    60
  • sponsor
    CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Updated on 22 March 2022

Summary

The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Description

This is a multicenter, open-label, phase I study aimed to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. In the study, 60 patients will be recruited into three dose groups. All patients will receive the treatment for the planned 8 cycles(28 days per cycle)until disease progression or unacceptable drug-related adverse events

Details
Condition Relapsed or Refractory Multiple Myeloma
Treatment Mitoxantrone Hydrochloride Liposome Injection, Bortezomib for Injection, Dexamethasone Acetate Tablets
Clinical Study IdentifierNCT05052970
SponsorCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Last Modified on22 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients fully understand and voluntarily participate in this study and sign informed consent
Aged 18-75 years, without gender limitation
Patients with relapsed or refractory multiple myeloma(confirmed by histologically or cytologically) who had received at least one prior line regular treatment
Patients have at least one of the following conditions:(1)Serum M protein≥10g/L;(2)Urine M protein≥200 mg/24h; (3)Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥100mg /L
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Laboratory tests meet the following conditions
Absolute neutrophil count (ANC) ≥1.5x10^9/L (No G-CSF treatment within 1 week prior to the laboratory test)
Platelet count ≥ 75x10^9/L (No platelet transfusion within 1 week prior to the laboratory test)
Total bilirubin ≤1.5upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN
Creatinine clearance(Ccr) ≥30mL/min
Females of childbearing potential must have a negative serum beta human chorionic
gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree
to use an effective contraception method for the duration of the study
treatment and 7 months after the last dose of study therapy
Males patients and their partners must agree to use an effective contraceptive method for the duration of the study treatment and 4 months after the last dose of study therapy
\-

Exclusion Criteria

Patients with amyloidosis or central nervous system invasion or on dialysis treatment
Life expectancy < 3 months
History of allergy to mitoxantrone hydrochloride or liposomes;or previous treatment with adriamycin or other anthracyclines, with the total cumulative dose (doxorubicin equivalent) ≥350 mg/m^2
History of allergy (except local injection reaction) or intolerance to bortezomib;or one of the following conditions occurred with prior bortezomib regimens: no treatment response (not reach MR),disease progression within 6 months after the end of last dose
History of contraindications or intolerance to dexamethasone
Any anti-myeloma drug treatment or radiotherapy within 4 weeks prior to the first dose; or enrolled in any other clinical trials of anti-myeloma drug within 3 months prior to the first dose
History of autologous hematopoietic stem cell transplantation within 6 months prior to screening
History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation
Adverse events from the previous treatment have not resolved to ≤ Grade 1 (except for alopecia, hyperpigmentation)
Patients with persistent Grade≥2 peripheral neuropathy or Grade 1 peripheral neuropathy with pain
Patients with impaired cardiac function or significant cardiac disease
HBsAg/HBcAb positive with HBV-DNA titer higher than the lower limit of the test value of the research center, or HCV antibody positive with HCV-RNA titer higher than the lower limit of the test value of the research center,or human immunodeficiency virus (HIV) antibody positive
Patients with obvious digestive system dysfunction, which may affect intake, transport and absorption of the study drug
Active bacterial, fungal or viral infections that require systemic treatment within 1 week prior to the first dose
Patients underwent major surgery within 6 weeks prior to the first dose, or had a surgical schedule during the study period
History of additional malignant tumor within 5 years, except for locally curable cancer that has been cured
Other medical conditions that, in the judgment of the investigator, may affect the patient's participation in this study
Pregnant or breastfeeding women
Not suitable for this study as decided by the investigator due to other reasons
\-
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note